Podcasts about Inflammatory

On this week's episode, I'm joined by Dr. Will Cole, one of the world's leading functional medicine experts, bestselling author, and host of The Art of Being Well podcast. Dr. Cole has helped transform thousands of lives, and in this conversation, he offers the tools to empower you to take control of your own health journey.We explore the foundations of optimal gut health, his “Inflammatory Core Four” and the benefits and important considerations of fasting. Dr. Cole explains the critical gut-brain connection through vagal tone, explaining why supporting this pathway may be more important than many realise.We also discuss orthorexia, and how to navigate wellness in an industry often dominated by extremes. Listen for a thoughtful and empowering conversation that may redefine how you approach your wellness.https://drwillcole.com/IG: @drwillcole// MORE FROM BRYONY // Get your free 7-day trial of Pilates by Bryony here. Use BEYOND30 to get a free 30-days on the app. Visit pilatesbybryony.com and shop our products here. Follow me on Instagram @bryonydeery @pilatesbybryony. Watch Beyond the Mat on YouTube. Produced by Dear Media. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Episode Highlights With LeighWhat POTS is and what the symptoms areHer daughter's story with POTS and how she learned so much through this storyThe mindset shifts that started the healing journey for themNutritional and lifestyle factors that they started with and the support team they builtHer daughter's decision that began the whole journey Inflammatory foods they removed and extra support they added inThe two foods groups worth experimenting with removing: gluten and dairy How exercise helped and the baby steps they started withThe most underrated healing tools: breath, sunshine, walkingResources MentionedTeen Wellness GuideOura Ring

See omnystudio.com/listener for privacy information.

Dr. Tom Roselle, DC discusses how gut toxicity can contribute to chronic inflammation. Look out for the signs including diarrhea, cramping, blood in the stool, loss of appetite and extreme fatigue. Listen to the Ageless Health with Dr. Tom Roselle, DC podcast at https://www.drtomroselle.com/ageless-health-podcast/ #agelesshealth @dctomroselledc @WMALDC @rosellecare #appliedkinesiology #constipation #hardstools #IBS #irritablebowelsyndrome #bloating #abdominalpain #nausea #stomachache #stomachcramps #stress #anxiety #inflammation #fat #weightloss #bowelhealth #bowlemovement #hydration #guthealth #nutrition #diet #diarrhea #migraine #guttoxicity

The Rich Zeoli Show- Full Episode (08/01/2025): 3:05pm- Rich notes that despite using 5% less electricity and 24% less gas, his bill has doubled thanks to Governor Phil Murphy's failed energy policies. This amounts to yet another reason why New Jersey can't afford to elect Mikie Sherrill in November. 3:10pm- According to the latest jobs report made available by the Labor Department, the U.S. economy only added 73,000 jobs in the last month—with unemployment rising from 4.1% to 4.2%. 3:15pm- In a post to Truth Social, President Donald Trump announced: “Based on the highly provocative statements of the Former President of Russia, Dmitry Medvedev, who is now the Deputy Chairman of the Security Council of the Russian Federation, I have ordered two Nuclear Submarines to be positioned in the appropriate regions, just in case these foolish and inflammatory statements are more than just that. Words are very important, and can often lead to unintended consequences, I hope this will not be one of those instances.” 3:30pm- Corey DeAngelis—Senior Fellow at the American Culture Project & Author of the book, “The Parent Revolution: Rescuing Your Kids from the Radicals Ruining Our Schools.”—joins The Rich Zeoli Show to discuss his latest article for The New York Post, “Randi Weingarten's Globalist Gambit Threatens Our Kids' Future Freedoms.” Plus, he reacts to Weingarten's ridiculous claim that halting federal defunding for NPR will result in democracy “backsliding.” 4:05pm- A new American Eagle clothing advertisement features Hollywood star Sydney Sweeney bragging about her “great jeans.” Far-left social media users, however, are ridiculously saying that the commercial is secretly promoting eugenics—insisting the ad's “great jeans” line really means “great genes.” American Eagle has now responded to the far-left's complaints, emphasizing the commercial was always just about “jeans.” 4:10pm- On Thursday night, former Vice President Kamala Harris made a guest appearance on The Late Show with Stephen Colbert where she promoted her soon to be released book, “107 Days.” During the interview, Harris bizarrely explained why she loves tethered earbuds rather than wireless airpods. 4:15pm- Rich will be on Fox News with Laura Ingraham tonight—but is he broadcasting out of the back of a van? 4:30pm- On Thursday, the Senate Judiciary Committee declassified intelligence—specifically the annex to former Special Counsel John Durham's report—allegedly revealing that Hillary Clinton personally approved of the efforts to promote the false narrative that then-candidate Donald Trump colluded with Russian officials during the 2016 presidential election. One declassified email exchange reveals that “HRC approved Julia's [Clinton foreign policy advisor Julianne Smith] idea about Trump and Russian hackers hampering U.S. elections. That should distract people from her own missing email, especially if the affair goes to the Olympic level.” 4:45pm- While speaking with Glenn Beck, Director of National Intelligence Tulsi Gabbard revealed there are still people working within the intelligence community that weaponized intelligence for political purpose—though, the Trump Administration is actively working on removing them. 5:05pm- CNN Senior Analyst Harry Enten evaluated the “Democrat brand”—and according to survey data it “is in the basement and it is total and complete garbage.” 5:15pm- On Thursday night, former Vice President Kamala Harris made a guest appearance on The Late Show with Stephen Colbert where she promoted her soon to be released book, “107 Days.” Harris was unable to name the current leaders of the Democratic Party. 5:40pm- George Stephanopoulos gets stuck in an elevator! Plus, should we all start watching the WNBA? This week one player lost her wig mid-game (leading to a fan being ejected for making fun of the incident), and in another game someone threw a bright green sex toy onto the court late in the 4th quarter! Also, are Justin ...

Ever wonder just how bad bad bacteria can be for your skin? We have been too. This week, we're joined by Dr. Sonal Choudhary as she walks us through the key relationship between the gut and the skin. Listen in as she discusses firmicutes and bacteroides, omega-3s and omega-6s, and IDS and IDCP. Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com.   Catch Dr. Choudhary live at #IDS2025 for more insights on the gut-skin connection and inflammatory dermatoses!   Sonal Choudhary, MD is an Assistant Professor of Dermatology and Dermatopathology at UPMC and a board-certified dermatologist and dermatopathologist. She is the founder of an innovative integrative dermatology clinic that blends conventional care with root-cause approaches, including functional testing, nutrition, and botanical therapies. A passionate educator and mentor, Dr. Choudhary trains advanced practice providers and leads research on the gut-skin axis, inflammatory skin diseases, and alopecia. She holds leadership roles in national dermatology initiatives and is committed to whole-person, evidence-based care. Her work bridges science and compassion to restore skin health from the inside out.

Research Explores the Association Between Immune System's Memory, Inflammatory Systemic Conditions, and PeriodontitisBy Today's RDH ResearchOriginal article published on Today's RDH: https://www.todaysrdh.com/research-explores-the-association-between-immune-systems-memory-inflammatory-systemic-conditions-and-periodontitis/Need CE? Start earning CE credits today at ⁠⁠⁠⁠⁠⁠⁠https://rdh.tv/ce⁠⁠⁠⁠⁠⁠⁠Get daily dental hygiene articles at ⁠⁠⁠⁠⁠⁠⁠https://www.todaysrdh.com⁠⁠⁠⁠⁠⁠⁠ Follow Today's RDH on Facebook: ⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/TodaysRDH/⁠⁠⁠⁠⁠⁠⁠Follow Kara RDH on Facebook: ⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/DentalHygieneKaraRDH/⁠⁠⁠⁠⁠⁠⁠Follow Kara RDH on Instagram: ⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/kara_rdh/

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Today, we're focusing on an often-overlooked peptide called VIP, short for Vasoactive Intestinal Peptide. The name might sound technical, but this peptide plays some important roles in the body. It helps regulate inflammation, supports nerve function, improves blood flow by relaxing blood vessels, and may even have benefits for things like chronic pain, including back pain. Let's get into it. What is VIP? We've talked about VIP before on a previous podcast, but it's been awhile and I'd like to start with the basics as a refresher.  VIP is a 28-amino acid neuropeptide that acts like a signaling molecule in both the central and peripheral nervous systems. Think of it like a chemical messenger that can influence a lot of different body systems. VIP belongs to the glucagon/secretin peptide superfamily, and it's found throughout the body, including your brain, intestines, lungs, and immune cells. Now, what does VIP actually do? Well it does quite a bit. VIP works by binding to specific receptors on cells—called VPAC1 and VPAC2—which trigger a chain reaction inside the body through something known as the cyclic AMP pathway. Once activated:  It relaxes smooth muscles, which helps open up blood vessels (vasodilation) and airways (bronchodilation) It stimulates secretion of water and electrolytes in places like the gut and pancreas—so yes, it helps with digestion too It's a major immune modulator, calming inflammation by regulating immune cell behavior  Neuroprotective role, supporting the survival and adaptability of neurons VIP in Medicine – What's the Buzz? VIP has been studied in a variety of conditions. Inflammatory diseases like rheumatoid arthritis and Crohn's Neurodegenerative conditions like Alzheimer's and Parkinson's Autoimmune diseases like osteoarthritis Respiratory conditions like pulmonary arterial hypertension (PAH), asthma, and chronic obstructive pulmonary disease (COPD) or due to mold toxicity But today, we're zooming in on something more tangible for a lot of people—back pain. VIP and Back Pain – What Do We Know? Let's get into the science here. VIP has recently caught attention for its potential role in intervertebral disc degeneration, which is one of the top causes of chronic low back pain. A 2024 study found that VIP receptors were significantly reduced in degenerated human discs—which is kind of a red flag. When VIP was given to mice for four weeks, researchers saw slowed degeneration, better structural proteins like aggrecan, and overall healthier discs on imaging. Promising, right? But here's the catch—this was a preclinical animal study. We still need human trials to confirm it works outside the lab. VIP and Joint Pain And when it comes to VIP and joint pain, there's a bit more research on VIP and osteoarthritis, especially when the spine is involved. In OA models, VIP was shown to lower pro-inflammatory cytokines—those molecules that contribute to pain and make joints hurt. But here's where it gets complicated: some studies report that VIP accumulation in joints might actually worsen pain. So... it's a bit of a paradox. So what's the takeaway? VIP can be helpful—but its role in pain management seems to depend on how much, where, and what kind of pain we're talking about. VIP in Peptide Therapy – Real-World Use? In peptide clinics—especially those using integrative or regenerative medicine approaches—VIP is sometimes part of treatment protocols for nerve-related pain and inflammation. It's often paired with other peptides like BPC-157 and TB-500. You can find some clinics that list VIP as a go-to for chronic pain, including back pain. But here's the reality check, clinical data is limited, success is anecdotal, it's pricey and results can vary from person to person. So while VIP might help reduce inflammation and slow tissue degeneration, it's not a substitute for tried-and-true pain management peptides like BPC-157. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, and as always, have a happy, healthy week.

In the first hour of today's edition of the show, Dan Caplis reacts to Donald Trump's damning accusations of Barack Obama and his administration.

On this episode, Dr. Sadaf continues her essential deep dive into vulvar health issues with a focused look at Desquamative Inflammatory Vaginitis (DIV). Learn all about this rare, yet profoundly impactful chronic inflammatory condition, often misdiagnosed as common infections like yeast or bacterial vaginosis. Dr. Sadaf goes over everything DIV, from the debilitating symptoms, its association with erosive lichen planus and the significant havoc it wreaks on patients' lives and self-esteem. This close look at DIV also includes an explanation of how it is diagnosed and what treatments are used in an effort to eventually restore comfort, hope, and a return to intimacy!Disclaimer: Anything discussed on the show should not be taken as official medical advice. If you have any concerns about your health, please speak to your medical provider. If you have any questions about your religion, please ask your friendly neighborhood religious leader. It's the Muslim Sex Podcast because I just happen to be a Muslim woman who talks about sex.To learn more about Dr. Sadaf's practice and to become a patient visit DrSadaf.comLike and subscribe to our YouTube channel where you can watch all episodes of the podcast!Feel free to leave a review on Apple Podcasts and share the show!Follow us on Social Media...Instagram: DrSadafobgynTikTok: DrSadafobgyn

Inflammatory diseases involve excessive or ongoing inflammation that damages tissues and affects many different human systems, including digestion, immunity, circulation, breathing, and the nervous system. The demand for anti-inflammatory treatments is growing quickly and is tipped to top a quarter of a trillion dollars within the decade as cases increase and new approaches to address inflammation emerge.This week, I had the chance to talk to Niels Riedemann, CEO and Founder of InflaRx, about his company's first-in-class approach to fighting inflammation, and what the future might hold for his “pipeline in a product”.01:26   Introducing Niels Riedemann04:28   InflaRx and its mission06:37   The competitive landscape in anti-inflammatory therapeutics07:21   The market for anti-inflammatories08:40   The challenge of taking a drug from R&D to commercialization11:06   The science behind the C5a and C5aR approach14:37   Why is InflaRx the first to focus on these selective inhibitors?19:18   The importance of the MAC formation21:05   InflaRx and its disease targets25:46   Applications beyond anti-inflammatories27:50   Lessons learned from the clinic29:54   Growth forecasts for InflaRx31:48   Different approaches to addressing inflammation33:51   The role of academia in breakthrough therapies36:11   Beyond Europe and North America, addressing the global demand for therapeuticsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Why is the immunology and inflammation market suddenly attracting a wave of investment?Let's Take a Closer Look at 7 Autoimmune Diseases Biotechs are Fighting to TreatJAK inhibitors: Are they a good option for treating inflammatory diseases and cancer?

Chronic disease can have a devastating impact on your life. It can be all too easy to give up and accept the new normal, but there are often ways to regain control. ⁠Dr. Terry Wahls⁠ not only found a way to slow the progression of her own disease, but she also developed a protocol to help others do the same. Dr. Wahls is recognized worldwide for her protocol which is transforming the lives of countless people. She is a clinical professor at the University of Iowa. Dr. Wahls conducts clinical trials into the efficacy of therapeutic lifestyle to treat multiple sclerosis-related symptoms. She is the author of ⁠The Wahls Protocol⁠ as well as her revolutionary ⁠cookbook⁠. In part one of our conversation, Dr. Wahls shares the specifics of her protocol. Before her diagnosis of multiple sclerosis, Dr. Wahls was an incredibly active woman. After seeking out various aggressive treatments for her condition, Dr. Wahls realized that it was up to her to take control of her health. Dr. Wahls came to realize that redesigning a paleo-diet to focus on the right nutrients could make a difference. Within months, she experienced massive improvements and is as active as ever. A key part of her recovery centers on feeding the mitochondria. With her redesigned diet, Dr. Wahls is able to better make use of the nutritional compounds that would otherwise be in supplements. Eating lots of green leafy, colorful, and sulfur-rich vegetables is a key part of this. Likewise, there are foods to avoid, particularly gluten and casein. Changing your habits and diet is easier said than done. Most practitioners know the struggle of patient compliance. Dr. Wahls shares some great advice for helping to motivate patients so that they can better take ownership of their health. Have you changed your diet in response to chronic disease? Tell me how it's going in the comments on the episode page!   My ⁠Your Longevity Blueprint course⁠ is currently 50% off to celebrate the launch of the podcast PLUS I'm throwing in a free personalized consultation!    In this episode: How a lack of success with conventional treatments led Dr. Wahls to develop her own MS protocol The role of mitochondria in maintaining cellular health The foods that make up the Wahls Protocol A great healthy recipe for meat lovers Inflammatory foods to avoid Why changing our diets is often so difficult Links & Resources: Use code COQ10 to get 10% off ⁠⁠⁠COQ10 Use code ENERGY to get 10% off ⁠⁠⁠MITOCHONDRIAL COMPLEX ⁠⁠⁠⁠Sinus Support Use code GLUTATHIONE to get 10% off ⁠GLUTATHIONE Multiple Sclerosis and NeuroImmune Summit 2.0: ⁠Learn more here⁠ ⁠Follow Dr. Terry Wahls online⁠ Follow Dr. Wahls on ⁠Facebook⁠ | ⁠Pinterest⁠ | ⁠Twitter⁠ | ⁠YouTube⁠   ⁠The Wahls Protocol⁠ ⁠The Wahls Protocol Cooking for Life⁠ ⁠Linus Pauling Institute⁠   ⁠Get your copy of the Your Longevity Blueprint book and claim your bonuses here⁠ ⁠Find Dr. Stephanie Gray and Your Longevity Blueprint online⁠   Follow Dr. Stephanie Gray on ⁠Facebook⁠ | ⁠Instagram⁠ | ⁠Youtube⁠ | ⁠Twitter⁠ | ⁠LinkedIn⁠ ⁠Integrative Health and Hormone Clinic⁠   ⁠Podcast Production by the team at Counterweight Creative⁠ 

On the latest episode of The Weekly Briefing from Capital Economics, Group Chief Economist Neil Shearing joins David Wilder to unpack the key developments in global macro and markets, including:What to expect as the ‘Liberation Day' tariff pause approaches expiryWhether the US and EU can strike a trade deal in timeWhy China is central to the US–Vietnam trade agreementWhat's really troubling about the passage of Trump's “big, beautiful” tax billWhat moves in gilt and sterling markets this week revealed about the UK Labour Party's fiscal credibilityAlso on the show, Senior Global Economist Ariane Curtis discusses her new in-depth report on the outlook for global trade amid rising tariffs. She explains why her forecasts challenge the narrative of deglobalisation and also shares highlights from our latest Global Economic Outlook, including China's looming slowdown and India's relative outperformance.Analysis and data referenced in this episode:Data: China-US Trade ReroutingData: Tariff Impact ModelRead: What do tariffs mean for global trade?Data: Euro-zone Debt Sustainability Monitor

Sleep detoxifies our brains! Refined sugars, junk food, and late-night snacking can interfere with sleep. If you want better sleep, eat earlier in the day. For the best sleep, have your last meal around 5:00 p.m. If you're waking at night to urinate, intermittent fasting and a low-carb diet can help. Inflammatory foods, such as grains, can also interfere with your sleep. High carbohydrate diets increase your need for vitamin B1, which reduces anxiety and tension.Kefir contains probiotics that can build up serotonin, which turns into melatonin, the sleep hormone. L. reuteri yogurt also contains helpful probiotics to improve sleep. Consume ½ cup daily; it doesn't have to be before bed.Try the following tips for better sleep to help you wake up early feeling refreshed and energized!

Sleep detoxifies our brains! Refined sugars, junk food, and late-night snacking can interfere with sleep. If you want better sleep, eat earlier in the day. For the best sleep, have your last meal around 5:00 p.m. If you're waking at night to urinate, intermittent fasting and a low-carb diet can help. Inflammatory foods, such as grains, can also interfere with your sleep. High carbohydrate diets increase your need for vitamin B1, which reduces anxiety and tension.Kefir contains probiotics that can build up serotonin, which turns into melatonin, the sleep hormone. L. reuteri yogurt also contains helpful probiotics to improve sleep. Consume ½ cup daily; it doesn't have to be before bed.Try the following tips for better sleep to help you wake up early feeling refreshed and energized:•Sleep in a 65 to 68 degree room•If you have cold feet at night, try sleeping with warm socks•Plants in the room can help oxygenate the space and improve sleep•The darker the environment, the better Light inhibits melatonin. Blue light from your computer or phone stimulates energy, while infrared lighting helps you wind down. Around 50% of the sun's rays are infrared and can penetrate several inches into the body. Infrared light helps you make vitamin D, which is vital for sleep and increasing melatonin. Since culture has pushed us away from sun exposure, sleep quality has declined. Alcohol will make you feel tired, but it interferes with deep sleep. Caffeine, tea, coffee, and chocolate act as stimulants and prevent sleep. Increase exercise to improve sleep. Stretching and massage can also help you relax. Here are a few more deep sleep tips that can significantly improve sleep quality:•Sleep on your right side•Focus on nose breathing •Reduce stress for better sleep•Ensure adequate sodium intake to maintain healthy cortisol levels •Increase potassium intake •Consume magnesium glycinate powder 1 hour before bed •Sound machine •Binaural beats •Use essential oils (Spikenard, vetiver)Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the author of the best-selling book The Healthy Keto Plan, and is the Director of Dr. Berg Nutritionals. He no longer practices, but focuses on health education through social media.

Most people think dental problems only affect their mouth, but that's where they're dead wrong. After my conversation with Dr. Jigar Gandhi, I'm convinced we've been missing a massive piece of the health optimisation puzzle, and this is where biological dentistry comes in. When I had my infected tooth removed, my shoulder pain, lung catch, and toe numbness disappeared within 48 hours, because each tooth connects to specific organ systems through 5,000-year-old meridian mapping. Your mouth is the gateway to chronic infections that can trigger autoimmune diseases, brain fog, and systemic inflammation throughout your entire body.  Join the Ultimate Human VIP community: https://bit.ly/4ai0Xwg Connect with Dr. Jigar Gandhi: Website: http://bit.ly/4l7hSX3 Website: http://bit.ly/3Goflsn YouTube: http://bit.ly/44EUv1c Instagram: http://bit.ly/4ezmKSy TikTok: http://bit.ly/4lfLIJe Find Authorised Biological Dentists:  http://bit.ly/4ntxxBD Study on Root Canals Causing Breast Cancer:  http://bit.ly/4lxgP2o IAOMT Position Paper on Human Jawbone Cavitations: http://bit.ly/3ZSDrlO Thank you to our partners: H2TABS - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg BODYHEALTH - USE CODE “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV BAJA GOLD - USE CODE "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa EIGHT SLEEP - SAVE $350 ON THE POD 4 ULTRA WITH CODE “GARY”: https://bit.ly/3WkLd6E COLD LIFE - THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp WHOOP - GET 1 FREE MONTH WHEN YOU JOIN!: https://bit.ly/3VQ0nzW MASA CHIPS - GET 20% OFF YOUR FIRST ORDER: https://bit.ly/40LVY4y VANDY - USE CODE “ULTIMATE20” FOR 20% OFF: https://bit.ly/49Qr7WE AION - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD A GAME - USE CODE “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij HAPBEE - FEEL BETTER & PERFORM AT YOUR BEST: https://bit.ly/4a6glfo CARAWAY - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/3Q1VmkC HEALF - GET 10% OFF YOUR ORDER: https://bit.ly/41HJg6S BIOPTIMIZERS - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/4inFfd7 RHO NUTRITION - USE CODE “ULTIMATE15” FOR 15% OFF: https://bit.ly/44fFza0 GENETIC TEST: ⁠https://bit.ly/3Yg1Uk9 Watch  the “Ultimate Human Podcast”: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka: Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X.com: https://bit.ly/3Opc8tf Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps: 00:00 Intro 04:14 What is an Organ? 07:15 Symptoms and Testings with Biological Dentistry 12:23 Inflammatory markers 15:00 Tooth removal and microscopic examination 17:02 Addressing Optimal Health with Biological Dentistry 19:26 Tooth removal procedure 21:08 Dental Medicine Taking the Spotlight 24:12 After a Root Canal 28:59 Outcomes after Biological Dentistry Procedures 30:54 Chronic and Autoimmune Disease Symptoms 39:27 Testimonials from Dr. Gandhi's Patients: http://bit.ly/4kBGGpj 46:26 Recognizing the Starting Point of the Existence of Diseases 51:38 Importance of Proper Oral Care Routine  56:41 When to See a Biological Dentist? 1:00:05 What does it mean to you to be an “Ultimate Human?” The Ultimate Human with Gary Brecka Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The Content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. Learn more about your ad choices. Visit megaphone.fm/adchoices

Host: Darryl S. Chutka, M.D. Guests: David H. Bruining, M.D., and Nayantara Coelho-Prabhu, M.B.B.S. An early diagnosis of inflammatory bowel disease is important in preventing long-term complications. Prompt treatment can improve quality of life, reduce the likelihood of hospitalizations, and help maintain remissions. However, establishing a diagnosis is often challenging due to the nonspecific and fluctuating nature of symptoms. Inflammatory bowel disease can also mimic other GI conditions. In addition, diagnostic confirmation usually requires a combination of blood tests, imaging, endoscopy, and histological analysis, making the process both time consuming and complex.  The topic for today's podcast is “Diagnosing Inflammatory Bowel Disease and Monitoring Modalities” and my guests are David H. Bruining, M.D., and Nayantara Coelho-Prabhu, M.B.B.S., from the Division of Gastroenterology and Hepatology at the Rochester campus of the Mayo Clinic. https://ce.mayo.edu/content/mayo-clinic-talks-inflammatory-bowel-disease   Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts   

Entertainment reporter Peter Ford has shed light on US President Donald Trump's "war path" with American TV network CNN.See omnystudio.com/listener for privacy information.

Dr. Jessica Eccles surveys the growing body of research that points to an association between neurodivergence, joint hypermobility, chronic pain, and anxiety. Learn why certain physical symptoms are more common in people with ADHD and autism, and about treatment options. Joint Hypermobility, Pain, & Neurodivergence: Additional Resources Read: ADHD at the Center: A Whole-Life, Whole-Person Condition Read: How ADHD Can Intensify Physical Health Conditions Read: ADHD, Autism, and Neurodivergence Are Coming Into Focus Read: The Gut-Brain Axis Could Accelerate Autism Understanding Watch: The Surprising Association Between ADHD & Inflammation Access the video and slides for podcast episode #560 here: https://www.additudemag.com/webinar/joint-hypermobility-adhd-autism-inflammation-pain/ This episode is sponsored by the podcast Sorry, I Missed This. Search for “Sorry I Missed This” in your podcast app or find links to listen at https://lnk.to/sorryimissedthisPS. Thank you for listening to ADDitude's ADHD Experts podcast. Please consider subscribing to the magazine (additu.de/subscribe) to support our mission of providing ADHD education and support.

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

The Utah Senator was confronted by fellow Senator Tina Smith after his post about the shooting in Minnesota. What happened next? Listen to the Senator and Tom Hauser on The WCCO Morning News. Photo courtesy of Kayla Bartkowski/Getty Images

Dr. Uma Naidoo founded and directs the first hospital-based Nutritional Psychiatry Service in the United States. She is the Director of Nutritional and Lifestyle Psychiatry at Massachusetts General Hospital (MGH) & Director of Nutritional Psychiatry at MGH Academy while serving on the faculty at Harvard Medical School. She was considered Harvard's Mood Food Expert and has been featured in the Wall Street Journal. Dr. Naidoo is also the national bestselling author of This Is Your Brain on Food and her newest book, Calm Your Mind with Food is available now.  In this fascinating rerun episode (first aired in 2020), Erin and Dr. Naidoo discuss her 2020 book, This Is Your Brain On Food. Key Topics: * Dr. Naidoo's journey as a psychiatrist and professional chef * How what we eat affects our brain * The origin of the gut/brain connection * The rise of mental health concerns * Food to avoid for mental well-being * Inflammatory foods * Orthorexia and food obsession * How to add more diversity in your diet * The impact of caffeine and alcohol on mental health Join Erin's monthly mailing list to get health tips and fresh meal plans and recipes every month: https://mailchi.mp/adde1b3a4af3/monthlysparksignup Preorder Erin's new book, Live Beyond Your Label, at erinbkerry.com/upcomingbook/

Dr. David Furman and Dr. Buck Joffrey discuss the complexities of immune aging, the role of inflammation in age-related diseases, and how artificial intelligence is being utilized to enhance research in this field. He introduces the concept of the inflammatory age clock, which measures biological aging through immune system signals, and explores potential therapeutic interventions, including nutraceuticals and therapeutic plasma exchange. The discussion also touches on the future of aging research, emphasizing personalized approaches and the democratization of diagnostics. Learn more about Dr. David Furman: https://www.buckinstitute.org/lab/furman-lab/

In this episode of the RCP Medicine podcast, Professor Ailsa Hart and Dr Eathar Shakweh discuss how to approach managing Inflammatory Bowel Disease (IBD) in the acute medical setting. This is the first episode of a 2-part series, with a focus on ulcerative colitis.  IBD is a common condition, affecting 1 in 123 people in the UK. The 2024 State of the IBD Care in the UK report highlighted the urgent need to shorten time to diagnosis and initiate early treatment to minimise the risk of IBD-related complications. Acute and general medicine physicians have an important role to play in diagnosing and managing IBD. This podcast will equip medics at all stages of training with the necessary knowledge to approach this heterogenous and complex condition. Professor Hart is Director of IBD Research at St Mark's Hospital, London, United Kingdom and a world-leading expert in IBD. Eathar is an IBD Clinical Research Fellow at St Mark's and Imperial, with a special interest in perianal fistulising Crohn's disease. Crohn's & Colitis UK (CCUK) Websitehttps://crohnsandcolitis.org.uk/This is a valuable resource for patients and healthcare professionals alike, containing a wealth of information on IBD investigation and management.British Society of Gastroenterology (BSG) guidelines on Inflammatory Bowel Disease (IBD) - 2019Lamb, Christopher Andrew et al. “British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.” Gut vol. 68,Suppl 3 (2019): s1-s106. doi:10.1136/gutjnl-2019-318484https://pubmed.ncbi.nlm.nih.gov/31562236/For interested listeners, these are the national guidelines for IBD diagnosis and management. Please note, the new guidelines for 2025 are pending release.RCP LinksEducation and learning | RCP Events | RCP Membership | RCP Improving care | RCP Policy and campaigns | RCP CreditsMusic by bensound.com

Jane Kirtley, Silha Professor of Media Ethics and Law at the University of Minnesota, joins John Williams to talk about ABC News firing correspondent Terry Moran after he criticized Stephen Miller and President Trump on social media. Jane also breaks down The Pew Research Center news media tracker on how Americans use and trust 30 media […]

Jane Kirtley, Silha Professor of Media Ethics and Law at the University of Minnesota, joins John Williams to talk about ABC News firing correspondent Terry Moran after he criticized Stephen Miller and President Trump on social media. Jane also breaks down The Pew Research Center news media tracker on how Americans use and trust 30 media […]

Send us a textOn this week's WTR Small-Cap Spotlight, we speak with Apimeds CEO Erik Emerson about the newly NYSE listed company and the development of Apitox, a purified honeybee venom, for knee osteoarthritis and multiple sclerosis. We discuss the therapeutic properties of bee venom and the clinical/regulatory plans to bring Apitox to the US market. Listen to learn more about Apimeds and its novel approach to treat inflammatory pain.

Jane Kirtley, Silha Professor of Media Ethics and Law at the University of Minnesota, joins John Williams to talk about ABC News firing correspondent Terry Moran after he criticized Stephen Miller and President Trump on social media. Jane also breaks down The Pew Research Center news media tracker on how Americans use and trust 30 media […]

Have you heard that seed oils are inflammatory and bad for you? What does science say about this? Does canola oil and linoleic acid really cause inflammation and lead to heart disease? These questions and more are tackled in this episode with one of the top 2% of scientists in the world Dr. Bill Harris who has been researching fatty acids for over 40 years We cover: Why are we so scared of seed oils and are they really damaging our bodies? What about the oxidation that comes with processing, pressuring and high heat? Do we need to replace seed and vegetable oils with something else? Should we be lowering our omega 6s and increasing omega 3s? Should we be testing our omega ratio? How should we be changing our diets to have better health outcomes? Why do we see so much conflicting research? Is it better to eat saturated fats like butter and coconut oil? What about the oxidation in omega 3 supplements Toxins, heavy metals and so much more   Dr. Bill Harris has been a leading researcher in the omega-3 fatty acid field for 40 years. He has over 360 scientific papers on fatty acids and health, the vast majority on omega-3. He has been on the faculty of three medical schools (Universities of Kansas, Missouri (at Kansas City), and South Dakota), and has received 5 NIH grants to study omega-3. He was the co-author on three AHA statements on fatty acids and heart health. As the co-inventor of the Omega-3 Index (and other omega-3 blood tests) and founder of OmegaQuant Analytics, Dr. Harris has been ranked among the top 2% of scientists worldwide based on the impact of his research.   omegaquant.com (OmegaQuant) and fareinst.org (Fatty Acid Research Institute) HACKMYAGE10 for 10% off your entire order @OmegaQuant.com (cannot be combined with other offers and expires July 31, 2025).   Contact Dr. Bill Harris: Facebook: @Omega3Index  Instagram: @OmegaQuant  YouTube: @OmegaQuantLab  LinkedIn: @OmegaQuant-Analytics  X: @OmegaQuant  Newsletter signup: https://omegaquant.activehosted.com/f/7   Give thanks to our sponsors: Qualia senolytics and brain supplements. 15% off with code ZORA here. Try Vitali skincare. 20% off with code ZORA here https://vitaliskincare.com Get Primeadine spermidine by Oxford Healthspan. 15% discount with code ZORA ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Get Mitopure Urolithin A by Timeline. 10% discount with code ZORA at https://timeline.com/zora Try Suji to improve muscle 10% off with code ZORA at TrySuji.com https://trysuji.com Get Magnesium Breakthrough by Bioptimizers. 10% discount with code HACKMYAGE at https://bioptimizers.com/hackmyage Try OneSkin skincare with code ZORA for 15% off https://shareasale.com/r.cfm?b=2685556&u=4476154&m=102446&urllink=&afftrack= Join ⁠⁠⁠Biohacking Menopause⁠⁠⁠ before July 1, 2025 to win free Vitali Skincare! 20% off with code ZORA at VitaliSkincare.com   Join the Hack My Age community on: Facebook Page: ⁠⁠⁠⁠⁠@⁠Hack My Age⁠     https://www.facebook.com/HackMyAge Facebook Group: ⁠⁠⁠⁠⁠⁠@⁠Biohacking Menopause⁠⁠⁠⁠⁠⁠ ⁠  Private Women's Only Support Group: https://hackmyage.com/biohacking-menopause-membership/ Instagram: ⁠⁠⁠⁠⁠@⁠HackMyAge⁠    Website: ⁠⁠⁠⁠⁠⁠HackMyAge.com⁠   

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Download the transcript here

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Listen to the podcast here

Chronic sinusitis might be doing more than just clogging your nose–it could be clouding your brain. In this episode of Backtable ENT, Dr. Aria Jafari, an assistant professor at the University of Washington and co-director of the Neuroendocrinology Advanced Sinus and Skull-base Surgery Fellowship, discusses the connection between sinusitis and cognitive dysfunction with hosts Dr. Gopi Shah and Dr. Ashley Agan. --- SYNPOSIS Dr. Jafari shares how his interest in this field developed and details his research on the relationship between chronic rhinosinusitis (CRS) and brain function. The conversation highlights the comprehensive impact of sinus inflammation on overall health, emphasizing the importance of viewing CRS as a whole-body condition. They also discuss patient experiences, the methodologies used to assess cognitive dysfunction, potential treatments, and what's next in the research frontier.---TIMESTAMPS00:00 - Introduction 06:18 - The Impact of CRS on Quality of Life14:02 - Understanding Brain Fog and Cognitive Dysfunction24:29 - Pathophysiology and Theories of Cognitive Dysfunction27:44 - Chronic Inflammation and Cognitive Effects28:59 - Impact of Biologics on Cognitive Function31:28 - Risk Factors for Cognitive Dysfunction35:02 - Olfactory Symptoms 37:13 - Future Research and Treatment Approaches45:31 - Conclusion and Final Thoughts --- RESOURCES Dr. Aria Jafari https://www.uwmedicine.org/bios/aria-jafari

About Ric Kealoha, MD:   Dr. Ric Kealoha is an American Physician specializing in functional and longevity medicine, with active medical licenses in four countries. As a forward-thinking leader in the holistic health revolution, Dr. Kealoha combines cutting-edge research, data-driven protocols, and patient-centered care to redefine how healthcare professionals and entrepreneurs approach wellness, performance, and disease prevention. With extensive experience treating high-achieving professionals, executives, and entrepreneurs, Dr. Kealoha has built a reputation for precision-driven, root-cause personalized medicine that optimizes human health beyond traditional allopathic clinical models. He is deeply committed to empowering people, healthcare professionals, and doctors by bridging the gap between functional integrative medicine, alternative therapies, and AI-powered health solutions. As one of the 4 visionaries behind MET@BOLICS+, Dr. Kealoha is spearheading an AI-driven revolution and transformation in personalized healthcare and functional medicine, leveraging technology to make science-backed holistic wellness accessible to millions worldwide. His mission is to disrupt outdated medical paradigms, combat misinformation, and create scalable, high-impact health solutions that drive both better patient outcomes and long-term investor value. With a track record of innovation and execution, Dr. Kealoha is positioning MET@BOLICS + as the premier AI-powered healthcare and wellness platform, merging profitability with purpose in a rapidly growing 200B   What We Discuss In This Episode: Issues with Traditional Hormone Testing/Treatment Basic blood tests often miss underlying issues (e.g. thyroid problems) Doctors frequently dismiss symptoms or use one-size-fits-all approaches Hormone replacement often uses synthetic/animal-derived hormones with side effects Lack of education on perimenopause/menopause for many doctors (only ~1 hour in med school) Advanced Hormone Testing and Analysis Comprehensive urine tests examine entire hormone system Detects xenoestrogens from plastics, pesticides, etc. linked to cancer risk Assesses body's ability to eliminate toxic forms of hormones Examines stress hormones like cortisol and their impact Key Factors Impacting Hormonal Health Environmental toxins (cosmetics, cleaners, plastics, etc.) Chronic stress and poor sleep Inflammatory diet (esp. fast food, high carb) Gut health issues ("leaky gut") Excess body fat producing estrogen Psychological/emotional factors Natural Approaches to Hormone Balance Detoxification via supplements (broccoli sprouts, DIM, glutathione, chlorella) Intermittent fasting (tailored for women's cycles) Ketogenic diet to reduce inflammation Increased water intake (3-5L daily, filtered) Stress reduction and mindset shifts Bioidentical hormones if needed Broader Health System Issues Distrust in medical/government institutions growing Many doctors resistant to new research/approaches Food industry practices contributing to obesity epidemic Need for patient and practitioner education on functional approaches   Connect With Dr. Ric Kealoha: Website: https://www.advancedwaysinhealing.com LinkedIn: https://www.linkedin.com/in/ric-kealoha-md-bsc-b6328417b/ Connect with Lynne: If you're looking for a community of like-minded women on a journey - just like you are - to improved health and wellness, overall balance, and increased confidence, check out Lynne's private community in The Energized Healthy Women's Club. It's a supportive and collaborative community where the women in this group share tips and solutions for a healthy and holistic lifestyle. (Discussions include things like weight management, eliminating belly bloat, balancing hormones, wrangling sugar gremlins,  overcoming fatigue, recipes, strategies, perimenopause & menopause, and much more ... so women can feel energized, healthy, and lighter, with a new sense of purpose. Website:  https://holistic-healthandwellness.com Facebook: https://www.facebook.com/holistichealthandwellnessllc The Energized Healthy Women's Club:  https://www.facebook.com/groups/energized.healthy.women Instagram: https://www.instagram.com/lynnewadsworth LinkedIn:  https://www.linkedin.com/in/lynnewadsworth   Free Resources from Lynne Wadsworth: ✨ Ready to Thrive in Midlife? Let's Make It Happen!

Send us a textDr. Michael Bernhardt, a dermatologist and clinical researcher, joins Dr. Erich Schramm to discuss the revolutionary advancements in psoriasis treatment over the past two decades. The doctors discuss how psoriasis is an inflammatory disease more than an autoimmune disease. They discuss what inflammation is, the inflammation pathway in the body, and how different medications can help suppress the body's out-of-control inflammatory response. They go over the history of psoriasis medications, which ones may be appropriate for different severities of the disease, and what's on the cutting edge of psoriasis treatment.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Skin of Color Issues - with Dr. Tia Paul! -Anterior cervical hypertrichosis -A new vascular anomaly: SeCVAUS -Can you just observe SCCis? -Early inflammatory morphe can mimic port-wine stains -Learn more about Dr. Paul at balancedskin.com/ or on Instagram/Tiktok @dr.tiapaul!Join Luke's CME experience on Jak inhibitors! ⁠rushu.gathered.com/invite/ELe31Enb69⁠Register for the U of U Practical Derm course!⁠medicine.utah.edu/dermatology/educ…ities/practical⁠Learn more about the U of U Dermatology ECHO model!⁠physicians.utah.edu/echo/dermatology-primarycare⁠Want to donate to the cause? Do so here!
Donate to the podcast: ⁠uofuhealth.org/dermasphere⁠
Check out our video content on YouTube:
⁠www.youtube.com/@dermaspherepodcast⁠
and VuMedi!: ⁠www.vumedi.com/channel/dermasphere/⁠
The University of Utah's Dermatology
ECHO: ⁠⁠physicians.utah.edu/echo/dermatology-primarycare⁠ -
⁠ Connect with us!
- Web: ⁠⁠dermaspherepodcast.com/⁠⁠ - Twitter: @⁠DermaspherePC⁠
- Instagram: dermaspherepodcast
- Facebook: ⁠www.facebook.com/DermaspherePodcast/⁠
- Check out Luke and Michelle's other podcast,
SkinCast! ⁠⁠healthcare.utah.edu/dermatology/skincast/⁠⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our
friends at:
- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)
- ⁠⁠www.levelex.com/games/top-derm⁠⁠ (A free dermatology game to learn
more dermatology!

On The Other Side of Midnight, Dominic starts the show talking about the killing of two Israeli embassy workers outside the Capital Jewish Museum. Learn more about your ad choices. Visit megaphone.fm/adchoices

Does this sound familiar?   Fatigue Brain fog Skin issues Joint pain   Symptoms like these are not random and they could be a sign of an underlying reaction to certain foods.     These sensitivities aren't always obvious and often go undetected, but with the right tools and a short elimination strategy, you can begin to identify your personal triggers and dramatically improve how you feel each day.     Join me on today's Cabral Concept 3392 as I go over the 5 most common inflammatory food sensitivities we see in our practice and what you can do to uncover whether they're affecting your health.   Enjoy the show, and let me know your thoughts! - - - For Everything Mentioned In Today's Show: StephenCabral.com/3392 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

We've compiled the top diets, treatments, and lifestyle tips to help you heal leaky gut. This guide is based on research as well as our experience successfully treating patients in our clinic. Watch now! We can help you heal your gut! Learn more about our virtual clinic:  https://drruscio.com/virtual-clinic/  

Seed oils have recently become a hotly debated topic in nutrition, fueled by sensational claims on social media. In this episode, the central theme is examining whether seed oils are truly harmful or if they've been unjustly demonized. The discussion tackles prevalent claims – that seed oils drive inflammation, oxidation, and chronic disease – and compares them against the current scientific evidence. This is highly relevant to nutrition science and clinical practice today, as many patients and practitioners are encountering conflicting information about vegetable oils. By exploring the origins of seed oils, their biochemical effects, health outcome data, and the misinformation ecosystem, the episode aims to clarify how omega-6 rich seed oils fit into a healthy diet and what evidence-based guidelines say. Timestamps 01:00 Understanding terms: PUFA, Linoleic Acid, Omega-6 05:20 Do seed oils cause inflammation? 12:44 Omega-3 and omega-6 16:43 Inflammatory markers and linoleic acid 19:22 Oxidation and cooking oils 26:25 Refining processes and health concerns 30:32 Health outcomes and polyunsaturated fats 35:18 Evidence cited by anti-seed oil proponents 43:48 Conclusions Related Resources Join the Sigma email newsletter for free Subscribe to Sigma Nutrition Premium Enroll in the next cohort of our Applied Nutrition Literacy course Sigma Statement: Seed Oils on Trial: Is the Panic Justified? Related podcast episodes: 502: Sydney Diet-Heart Study – Is Linoleic Acid Causing Heart Disease? 504: Vegetable Oil vs. Saturated Fat – Analysis of the LA Veterans Study 505: Oslo Diet-Heart Study: Cholesterol-lowering Diets & Cardiovascular Events 329: Diet & Inflammation

Story at-a-glance Women with chronic migraines and body-wide pain were far more likely to have poor oral health, with over half falling into the lowest oral health categories in a new study Specific oral bacteria, including Mycoplasma salivarium and Gardnerella vaginalis, were significantly more common in women who reported frequent migraines and widespread pain Harmful oral microbes don't stay in your mouth; once gum tissue is inflamed, these bacteria enter your bloodstream, disrupt the immune system, and trigger systemic pain A less diverse oral microbiome was found in women with migraines and gut pain, making it easier for pain-triggering bacteria to dominate and inflame nerve pathways Inflammatory chemicals produced by oral bacteria — like calcitonin gene-related peptide (CGRP) and vascular endothelial growth factor (VEGF) — are directly involved in migraine and fibromyalgia, showing how poor oral hygiene can set off whole-body pain responses

Host: Danielle O'Laughlin, PA-C, MS and Jenna Wygant, APRN, CNP, DNP Guest: Danielle O'Laughlin, PA-C, MS In this episode, along with host/guest Danielle O'Laughlin, PA-C, MS, we will discuss benign, inflammatory breast conditions. We will cover how to differentiate between common issues such as mastitis, breast abscess, fat necrosis, galactorrhea, and gynecomastia. We'll walk through the key signs and symptoms to watch for and explore how each condition is diagnosed and treated. This episode offers valuable insights into these non-cancerous yet very important conditions. By the end of this podcasts, listeners will be able to: Differentiate the benign, inflammatory breast conditions including mastitis, breast abscess, fat necrosis, galactorrhea, and gynecomastia. Recognize the signs and symptoms for benign, inflammatory breast conditions. Summarize the diagnosis and treatment options for benign, inflammatory breast conditions. Learn more about this series: Mayo Clinic Talks: Obstetric and Gynecologic Health | Mayo Clinic School of Continuous Professional Development Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

Inflammatory markers can double within six hours of eating a pro-inflammatory meal. Which foods are the worst, and which ones reduce inflammation? What does an anti-inflammatory diet look like?

Inflammatory bowel diseases like ulcerative colitis remain among the most difficult chronic conditions to manage — but new science at the intersection of microbiome research and biotechnology may offer hope.In this episode of The Mind-Gut Conversation, I sit down with Dr. Deanna Gibson, microbiome researcher and cofounder of Melius Microbiomics, to explore how genetically engineered microbial medicines could transform the future of IBD treatment — and what it will take for patients and the medical community to embrace them.In this conversation, we explore:· How Dr. Gibson's research led to the development of BioPersist™ and BioColonize™ for IBD.· Why new microbiome-targeted therapies are urgently needed — especially for younger patients in whom ulcerative colitis is on the rise.· What makes BioPersist™ different from traditional probiotics and current IBD treatments.· How genetically engineered microbial medicines (GEMMs) represent a new generation of gut therapies.· Early research findings that support BioPersist™ as a promising treatment for ulcerative colitis.· Challenges in gaining public trust for novel biotech therapies amid growing skepticism.· Exciting new discoveries in microbiome science — and the future potential for live biotherapeutics beyond IBD.If you're curious about the exciting direction where gut health research is headed — and how the microbiome may change the way we treat chronic disease — this episode is for you.Tune in and join the conversation!Disclaimer: Dr. Mayer is the Chief Medical Officer of Melius Microbiomics and has been involved in the commercial development of Genetically Engineered Microbial Medicines (GEMMs).

Story at-a-glance Ginger has a long history of soothing digestive issues and modern research confirms its ability to reduce gut inflammation and support intestinal healing Inflammatory bowel disease (IBD) increases the risk of serious health issues.IBDs like Crohn's disease and ulcerative colitis cause diarrhea, abdominal pain, and fatigue, increasing the risk of malnutrition, intestinal damage, and colorectal cancer if left untreated A recent study found that furanodienone (FDN) in ginger activates the pregnane X receptor (PXR), which reduces gut inflammation and oxidative stress. It also strengthens the intestinal barrier to prevent harmful bacteria from entering the bloodstream Early use of ginger compounds leads to better outcomes, with reduced symptom severity and faster recovery in gut inflammation, especially when started at the first signs of digestive issues Another study found that gingerols and shogaols suppress immune overactivity, lowering IL-1β and TNF-α while blocking key inflammatory pathways that worsen chronic gut conditions

Today, along with my expert guest, I'll be tackling inflammation, anti-inflammatory foods, and the role of inflammation in our fat loss progress (or lack thereof). CONNECT with Lindsay Cotter at www.cottercrunch.com. Here's the discount link for the anti-inflammatory 21-day meal plan and diet guide, which is valid through the year. For more detailed answers from the podcast interview, here are Lindsay's notes. ENROLL in my next FASTer Way 6-week online class at https://www.fasterwaycoach.com/AMYBRYAN CONNECT with Amy Bryan any of the following ways:  SCHEDULE a discovery call, VOICE MESSAGE me, JOIN my free Facebook community group, and DOWNLOAD my latest freebies at www.linktr.ee/amybryanfasterway EMAIL me at amy@fatlossschool.net

Rewiring Your Vagus Nerve: A Functional ApproachWhile vagus nerve exercises like cold plunges and humming are popular, this episode explores a deeper functional perspective. What if underlying factors like mineral imbalances, gut issues, mold exposure, or structural misalignments are blocking your vagal function?The Mineral ConnectionYour vagus nerve functions as your body's electrical system, with minerals as crucial conductors. Hair Tissue Mineral Analysis reveals important patterns:- Calcium/Magnesium Ratio: Excessive calcium dominance keeps you stuck in "fight or flight"- Calcium/Phosphorus Ratio: Ideally balanced at 2.3:1 for optimal function- Potassium Levels: Low levels signal insufficient nerve energy- Heavy Metal Burden: Toxic metals hijack nerve function by stealing mineral binding sites"Your vagus nerve is your digestive system's power cord. Mineral imbalances create short circuits!"The Gut-Vagus ConnectionYour gut contains the second largest neural system after the brain. Comprehensive stool testing can identify issues affecting vagal function:- Low microbial diversity correlates with reduced vagal tone- Deficiencies in butyrate-producers deprive the nerve of energy- Dysbiosis creates inflammation that dampens signalingThis creates a feedback loop: poor vagal tone worsens digestive function, increasing dysbiosis, further impairing vagal tone.Mold ExposureMold illness disrupts vagus nerve function through:- Direct neurotoxicity to vagal nuclei- Mitochondrial damage impairing energy production- Inflammatory cascades that dampen vagal toneMany experience treatment resistance because underlying mycotoxin burden continues suppressing function.Structural ConsiderationsThe vagus nerve can physically get "pinched" due to:- Cranial misalignments- Neck tension- Rib cage restrictions- Abdominal compressionThis explains why bodywork sometimes dramatically improves digestion when supplements haven't helped.Practical Support StrategiesWhile addressing root causes, try:1. Singing: Creates vibrations that stimulate the vagus2. Essential Oils: Applied diluted behind the ears3. Digestive Bitters: Trigger vagal firing4. Omega-3 Fatty Acids: Provide building blocks for nerve structureThe Holistic ApproachRather than isolated "hacks," assess your unique terrain. When we restore harmony to the entire ecosystem, vagal tone naturally improves, with benefits cascading throughout your physiology.Looking for deeper support? Visit the "Work With Me" page on my website to learn about my approach to mineral balancing and microbiome optimization – two key pillars that profoundly affect vagus nerve function and overall health. Mineral Foundations Course HERE Learn more about how you can I can work together HERE Book an initial health session HERE Join my newsletter HERE If you are interested in becoming a client and have questions, reach out by emailing me: connect@lydiajoy.me Find me on Instagram : @ Lydiajoy.me OR @ holisticmineralbalancing

Biohacking for Longevity: Extending Your Health Span. In this episode of "Leyla Weighs In," registered dietician and nutritionist Leyla Muedin discusses the concept of biohacking and its potential to extend lifespan and health span. Leyla explores various biohacking strategies such as diet optimization, regular physical activity, stress management, enhancing sleep quality, and maintaining strong social connections. She emphasizes the importance of epigenetics, targeted lifestyle changes, and advanced medical interventions like stem cell therapy. You will learn practical biohacking tips, including the benefits of intermittent fasting, the significance of exercise, and how to use wearable technology for health tracking. Leyla also highlights the role of supplements and personalized nutrition in promoting longevity, alongside maintaining good dental health and a sense of purpose. Through these combined efforts, Leyla aims to inspire listeners to not only live longer lives but to enjoy better health and vitality.

Dr. Sujatha Kekada is the Head Physician and Co-Founder of AmrtaSiddhi Ayurvedic Clinic in Ubud, Bali. She chats with Colette about inflammatory disorders in the urinary system and they discuss the following: The Ayurvedic perspective on the urinary system and the doshas involved. The root cause of inflammation. Dr. Sujatha covers the following disorders: Burning urination Urinary tract infections Cystitis Kidney infections Kidney stones Common causes of urinary tract infections. How the emotion of fear can play a role in these disorders. Tips to prevent these disorders from manifesting * Check out Dr. Sujatha's website here.... amrtasiddhi.com * Click here to learn more about discounted group Digestive Reset Cleanse starting March 28th, 2025 * Visit Colette's website www.elementshealingandwellbeing.com  Online consultations & Gift Vouchers Private at-home Digestive Reset Cleanse tailored to you Educational programs - Daily Habits for Holistic Health Have questions before you book? Book a FREE 15 min online Services Enquiry Call * Join the Elements of Ayurveda Community! * Stay connected on the Elements Instagram and Facebook pages. * Enjoy discounts on your favourite Ayurvedic products: Banyan Botanicals - enter discount code ELEMENTSOFAYURVEDA at checkout for 15% off your first purchase.** Divya's  - enter discount code ELEMENTSOFAYURVEDA15 at checkout for 15% off your first purchase.** Kerala Ayurveda - enter discount code ELEMENTS15 to receive 15% off your first purchase.** **Shipping available within the U.S. only. * Thanks for listening!  

The Inflammatory Reset: My Experience Following the Protocol It's been a while since we've done a book club episode, and I'm excited to dive into The Inflammatory Reset by Dr. Josh Redd. This book is all about reducing chronic inflammation through diet, lifestyle changes, and functional medicine approaches. I've been following the protocol for at least 30 days - in the episode I'll share more about why.

Join James Kustow, BMBS, MRCPsych, to learn about the emerging research that may explain ADHD's unexpected associations with inflammatory conditions like allergy and autoimmunity — and a surprisingly strong link with hypermobility syndrome. ADHD and Physical Health: More Resources Read: How ADHD Can Intensify Physical Health Conditions Free Download: Lifestyle Changes for Adults with ADHD Read: Chronic Fatigue Twice as Likely Among Children with ADHD Access the video and slides for podcast episode #545 here: https://www.additudemag.com/webinar/thyroid-adhd-inflammation-autoimmune-disease/ Thank you for listening to ADDitude's ADHD Experts podcast. Please consider subscribing to the magazine (additu.de/subscribe) to support our mission of providing ADHD education and support.